Treatment options after failure of local curative treatments in prostate cancer: a controversial issue

Schulman, Claude; Altwein, Jens E.; Zlotta, Alexandre R.

doi:10.1046/j.1464-410x.2000.00941.x

Cited by 11 publications

(4 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to medical factors, physician practice patterns and patient preferences influence the relationship between disease recurrence and additional treatment [18,19]. Increased frequency among black patients of posttreatment assessments of black patients or a greater propensity to institute therapy in black patients once biochemical progression is noted could partly account for the results we found.…”

Section: Discussionmentioning

confidence: 82%

Racial Differences in Clinical Progression Among Medicare Recipients After Treatment for Localized Prostate Cancer (United States)

Cohen

Schoenbach

Kaufman

et al. 2006

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 82%

Racial Differences in Clinical Progression Among Medicare Recipients After Treatment for Localized Prostate Cancer (United States)

Cohen

Schoenbach

Kaufman

et al. 2006

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

“…Prostate cancer is the most common invasive cancer diagnosed in men and the second leading cause of male cancer-associated mortality in the United States (US) [ 1 ]. The majority (79%) of patients with prostate cancer are diagnosed at a localised stage [ 2 ], which is potentially curable using radical prostatectomy, external beam radiotherapy (EBRT), or brachytherapy [ 3 ]. However, about 35% to 60% of men undergoing the initial curative effort will experience disease recurrence [ 4 , 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro

Lim

Baird

Greene

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: Enzalutamide is part of the treatment regimen for metastatic castration-resistant prostate cancer (MCRPC). However, both intrinsic and acquired resistance to the drug remain substantial clinical quandaries. circRNAs, a novel type of non-coding RNA, have been identified in a number of cancers including prostate cancer and have been associated with cancer development and progression. circRNAs have shown great potential as clinically useful blood-based ‘liquid biopsies’ and as therapeutic targets in prostate cancer. The aim of this study was to examine the role of circRNA transcripts in enzalutamide-resistant prostate cancer cells and assess their utility as biomarkers. Methods: An isogenic cell line model of enzalutamide resistance was subjected to circRNA microarray profiling. Several differentially expressed circRNAs, along with their putative parental genes were validated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). circRNAs of interest were stably overexpressed in the control cell line and drug sensitivity was assessed using an ELISA-based proliferation assay. The candidate circRNA, hsa_circ_0001275, was measured in patient plasma samples using RT-droplet digital PCR (RT-ddPCR). Results: hsa_circ_0001275 and its parental gene, PLCL2, were significantly up-regulated in strongly resistant clones vs. control (p < 0.05). Overexpression of hsa_circ_0001275 in the control cell line resulted in increased resistance to enzalutamide (p < 0.05). While RT-ddPCR analysis of hsa_circ_0001275 expression in plasma samples of 44 clinical trial participants showed a trend that mirrored the stages of disease activity (as defined by PSA level), the association did not reach statistical significance. Conclusions: Our data suggest that increased levels of hsa_circ_0001275 contribute to enzalutamide resistance. hsa_circ_0001275 plasma expression showed a trend that mirrors the PSA level at specific disease time points, indicating that circRNAs mirror disease recurrence and burden and may be associated with enzalutamide resistance.

show abstract

“…Approximately 79% of patients with prostate cancer are diagnosed at a localized stage based on the Surveillance, Epidemiology and End Results Program (SEER) data [ 3 ]. Therapeutic options such as radical prostatectomy, external beam radiotherapy (EBRT) or brachytherapy are primarily recommended for men with localized curative prostate cancer [ 4 ]. Despite initial curative effort by radical prostatectomy for localized disease, approximately 35% of men will experience a biochemical recurrence [ 5 ], and a higher recurrence rate of 40–60% has been witnessed after EBRT or brachytherapy [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer—From Cell Line Models to Liquid Biopsies

et al. 2018

View full text Add to dashboard Cite

The treatment landscape of prostate cancer has evolved rapidly over the past five years. The explosion in treatment advances has been witnessed in parallel with significant progress in the field of molecular biomarkers. The advent of next-generation sequencing has enabled the molecular profiling of the genomic and transcriptomic architecture of prostate and other cancers. Coupled with this, is a renewed interest in the role of non-coding RNA (ncRNA) in prostate cancer biology. ncRNA consists of several different classes including small non-coding RNA (sncRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA). These families are under active investigation, given their essential roles in cancer initiation, development and progression. This review focuses on the evidence for the role of RNAs in prostate cancer, and their use as diagnostic and prognostic markers, and targets for treatment in this disease.

show abstract

Treatment options after failure of local curative treatments in prostate cancer: a controversial issue

Cited by 11 publications

References 71 publications

Racial Differences in Clinical Progression Among Medicare Recipients After Treatment for Localized Prostate Cancer (United States)

Racial Differences in Clinical Progression Among Medicare Recipients After Treatment for Localized Prostate Cancer (United States)

hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro

RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer—From Cell Line Models to Liquid Biopsies

Contact Info

Product

Resources

About